Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of New General Counsel



On January 4, 2022, Esperion Therapeutics, Inc. (the "Company") announced the
appointment of Benjamin O. Looker as the Company's General Counsel pursuant to
the terms of an employment agreement with Mr. Looker (the "Looker Agreement"),
effective as of January 1, 2022 (the "Start Date").

Mr. Looker, 39, joins the Company after serving as General Counsel of Trillium
Therapeutics from April 2021 until its acquisition by Pfizer Inc. in November
2021. From May 2019 to April 2021, he was Vice President, Head of US Legal and
Global Business Operations at MorphoSys US Inc. Prior to that, Mr. Looker held
roles of increasing responsibility at EMD Serono, Inc. from July 2013 to May
2019. Mr. Looker received his undergraduate degree from Boston College and his
juris doctor degree from Boston College Law School.

Pursuant to the terms of the Looker Agreement, Mr. Looker is entitled to an
annual base salary of $375,000. Commencing in calendar year 2022, Mr. Looker
will also be eligible to be considered for an annual bonus targeted at 40% of
his base salary (the "Target Bonus"), subject to the CEO's assessment of his
performance as well as business conditions of the Company. Pursuant to the terms
of the Looker Agreement, Mr. Looker will receive (i) an option to purchase
100,450 shares of the Company's common stock, and (ii) 70,800 restricted stock
units, each of which will vest over four years in accordance with the terms and
conditions of the Company's Stock Option and Incentive Plan, as may be amended,
and the applicable stock option and restricted stock unit agreements.

Mr. Looker is eligible to participate in the Company's employee benefit plans
generally available to full-time employees, subject to the terms of those plans.
Pursuant to the terms of the Looker Agreement, if Mr. Looker's employment is
terminated, within the twelve (12) month period commencing with a Sale Event (as
defined in the Looker Agreement), by the Company other than for Cause (as
defined the Looker Agreement) or by Mr. Looker for Good Reason (as defined in
the Looker Agreement ), subject to Mr. Looker's signing the separation agreement
and release and the separation agreement and release becoming irrevocable, he
will be entitled to receive: (a) an amount equal to the sum of (i) one (1) times
his base salary in effect immediately prior to the termination (or his base
salary in effect immediately prior to the Sale Event, if higher), and (ii) his
Target Bonus; and (b) if he was participating in the Company's group health plan
immediately prior to the date of termination and elects COBRA health
continuation, a lump sum cash payment in an amount equal to the monthly employer
contribution that the Company would have made to provide health insurance to his
if he had remained employed by the Company for twelve months after the date of
termination. However, in the event that Mr. Looker's employment is terminated,
at any time other than during the twelve (12) month period commencing with a
Sale Event, by the Company other than for Cause, subject to his signing the
separation agreement and release and the separation agreement and release
becoming irrevocable, Mr. Looker will be entitled to receive: (a) an amount
equal to nine (9) months of his annual base salary in effect immediately prior
to the termination; and (b) if he was participating in the Company's group
health plan immediately prior to the date of termination and elects COBRA health
continuation, a monthly cash payment for nine (9) months or his COBRA health
continuation period, whichever ends earlier, in an amount equal to the monthly
employer contribution that the Company would have made to provide health
insurance to Mr. Looker if he had remained employed by the Company.

In connection with Mr. Looker's appointment as General Counsel, he will enter
into the Company's standard form of indemnification agreement, a copy of which
was filed as Exhibit 10.8 to the Company's Registration Statement on Form S-1
(File No. 333-188595) filed with the Securities and Exchange Commission ("SEC")
on May 14, 2013. Pursuant to the terms of the indemnification agreement, the
Company may be required, among other things, to indemnify Mr. Looker for some
expenses, including all reasonable attorneys' fees, judgments, fines and
settlement amounts actually and reasonably incurred by Mr. Looker in third-party
proceedings arising out of his service as one of the Company's officers.

Mr. Looker has no family relationship with any of the executive officers or
directors of the Company. There are no arrangements or understandings between
Mr. Looker and any other person pursuant to which he was appointed as an officer
of the Company.

In connection with Mr. Looker's appointment, effective as of January 1, 2022,
the Board of Directors of the Company designated Mr. Looker as an "executive
officer" of the Company as such term is defined under Rule 3b-7 under the
Securities Exchange Act of 1934, as amended, or the Exchange Act, and an
"officer" as such term is defined under Rule 16a-1(f) of the Exchange Act.

The foregoing summary of the Looker Agreement does not purport to be complete
and is qualified in its entirety by reference to the complete text of the Looker
Agreement, a copy of which is attached as Exhibit 10.1.

--------------------------------------------------------------------------------

Item 7.01. Regulation FD Disclosure.



On January 4, 2022, the Company issued a press release announcing the
appointment of Mr. Looker as the Company's General Counsel. A copy of the press
release is attached hereto as Exhibit 99.1 and is incorporated into this Item
7.01 by reference.

The information in this Current Report on Form 8-K and Exhibit 99.1 attached
hereto is intended to be furnished and shall not be deemed "filed" for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act") or otherwise subject to the liabilities of that section, nor shall it be
deemed incorporated by reference in any filing under the Securities Act of 1933,
as amended, or the Exchange Act, except as expressly set forth by specific
reference in such filing.

Item 9.01. Financial Statements and Exhibits.



d) Exhibits.
Exhibit No.                                               Description

      99.1                 Press Release dated J    anuary 4, 2022    .
      10.1                 Employment Agreement, dated     January     1

, 2022 , by and between

Esperion Therapeutics, Inc. and     Benjamin O.

Looker.


                         The cover page from this Current Report on Form

8-K, formatted in Inline


       104               XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses